NCT03967223 2026-02-25
IGNYTE-ESO
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
Clinical Trials
13 trialsNCT04794127 2026-02-18
TRABEPIO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT04044768 2026-02-06
Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT03063632 2023-10-25
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT02992743 2023-04-11
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
GlaxoSmithKline
Phase 2 Completed
NCT02821507 2022-04-20
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Leiden University Medical Center
Phase 2 Completed
NCT03989596 2021-02-01
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT03651375 2021-01-22
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT02609984 2020-07-07
IMDZ-C232
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT03397186 2019-09-10
Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT03816475 2019-06-17
LIPOMYX
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT00579501 2014-05-07
Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00633165 2010-02-26
SMI-BRS-202
Systems Medicine LLC
Phase 2 Unknown